Drug Safety Monitoring Information

Drug Safety Monitoring Information

Analysis of administrative decisions of foreign regulatory authorities on the recall of medicines and/or the need for changes in the instructions for their medical use due to changes in the safety proﬁle, conducted by experts of the Scientiﬁc Centre for Expert Evaluation of Medicinal Products reveal...

Full description

Saved in:

Bibliographic Details
Main Authors:	E. V. Shubnikova, E. O. Zhuravleva, N. Yu. Velts, P. M. Giulakhmedova, A. A. Druzhinina
Format:	Article
Language:	Russian
Published:	Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2021-07-01
Series:	Безопасность и риск фармакотерапии
Subjects:	adverse reactions postmarketing studies security proﬁle drugs instructions for medical use pharmacovigilance
Online Access:	https://www.risksafety.ru/jour/article/view/218
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Drug Safety Monitoring—International Information
by: E. V. Shubnikova, et al.
Published: (2020-12-01)

Analysis of Administrative Decisions of Foreign Regulatory Authorities
by: Information relevant
Published: (2019-09-01)

Topical Issues of Drug Safety, Possibilities of Improving of Pharmacovigilance
by: M. V. Zhuravleva, et al.
Published: (2019-09-01)

Recommendations on Informational Monitoring of the Safety and Efficacy of Medicinal Products in the Russian Federation as Part of Pharmacovigilance
by: K. S. Milchakov
Published: (2022-10-01)

Rational Organisation of Adverse Drug Reaction Monitoring
by: L. V. Shukil, et al.
Published: (2022-10-01)

EVALUATION OF SAFETY OF DRUG THERAPY IN CLINICAL PRACTICE
by: M. N. Kostyleva, et al.
Published: (2015-03-01)

Levofloxacin: Analysis of Information on Adverse Reactions from Russian Spontaneous Report Database
by: S. K. Zyryanov, et al.
Published: (2020-05-01)

Problematic aspects of participation of pharmacists in the system of pharmacovigilance in Russia
by: E. N. Tkhoseva, et al.
Published: (2022-06-01)

COMPARATIVE REVIEW OF METHODOLOGIES FOR ESTIMATING THE COST OF ADVERSE DRUG REACTIONS IN THE RUSSIAN FEDERATION AND BRAZIL
by: G. I. Syraeva, et al.
Published: (2021-03-01)

Drug-induced pulmonary edema: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS)
by: Zilan Zhong, et al.
Published: (2025-08-01)

MONITORING OF DRUG SAFETY IN CLINICAL PRACTICE
by: N. V. Verlan, et al.
Published: (2017-02-01)

Clinical and pharmacological monitoring of drug safety in pediatrics
by: N. V. Verlan, et al.
Published: (2016-05-01)

Drug Prescribing Trends and Safety Profile in Pediatric Care: Observations from a Tertiary Care Center
by: Farangipet Fathima, et al.
Published: (2021-04-01)

Monitoring of drug safety
by: B. K. Romanov, et al.
Published: (2022-06-01)

Assessment of knowledge and perceptions of pharmacy students toward pharmacovigilance activities, and their predictors: a cross-sectional study in Palestine
by: Rami Mosleh, et al.
Published: (2025-07-01)

Expert Evaluation of Pharmacovigilance System Documents Included in the Registration Dossier
by: I. I. Snegireva, et al.
Published: (2020-12-01)

Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)
by: N. Yu. Velts, et al.
Published: (2024-07-01)

Advances in Pharmacovigilance in India: Role of Mobile Application
by: Rajpushpa Labh, et al.
Published: (2020-07-01)

Psychotropic drug-induced adverse drug reactions in 462,661 psychiatric inpatients in relation to age: results from a German drug surveillance program from 1993–2016
by: Johanna Seifert, et al.
Published: (2024-11-01)

Analysis of the Causes for Renal Dysfunction during Antibiotic Therapy in a Patient with Lyme Disease
by: N. Yu. Velts, et al.
Published: (2022-10-01)

Retrieval and analysis of cyclopentolate hydrochloride eye drops related adverse drug reaction signals based on OpenFDA
by: WANG Jing, et al.
Published: (2025-04-01)

Exposure to potential drug-antimicrobial agent interactions in primary health care
by: Nikolić Božana, et al.
Published: (2018-01-01)

Pharmacovigilance as an imperative of modern medicine - experience from Montenegro
by: Mugoša Snežana, et al.
Published: (2017-01-01)

PECULIARITIES OF PATIENTS' PERCEPTION AND UNDERSTANDING OF INSTRUCTIONS FOR MEDICAL APPLICATION OF DRUGS
by: L. M. Unhurian
Published: (2015-09-01)

Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review
by: A. V. Kryukov, et al.
Published: (2022-12-01)

A national pharmacovigilance centre perspective on pandemic preparedness - lessons learned from the COVID-19 pandemic
by: Florence van Hunsel, et al.
Published: (2025-08-01)

ANTITHROMBOTIC THERAPY SAFETY MONITORING BASED ON SPONTANEOUS REPORTS
by: O. V. Shatalova, et al.
Published: (2015-09-01)

Approaches to Assessing the Safety of Medicines during the COVID-19 Pandemic Using the Example of Azithromycin
by: Yu. M. Gomon, et al.
Published: (2022-10-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system
by: Yaqian Tan, et al.
Published: (2025-08-01)

Development of lactation and breast/chestfeeding adverse event terminology (LaBAET) through a Delphi consensus approach
by: Katarzyna M. Maksym, et al.
Published: (2025-07-01)

Bases for the study of the safety of medicines. The spectrum of rare and unexpected ad-verse reactions of bisphosphonates
by: I S Dydykina, et al.
Published: (2011-12-01)

Safety of COVID-19 vaccines
by: B. K. Romanov
Published: (2022-12-01)

Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database
by: Tongtong Wang, et al.
Published: (2025-04-01)

Drug-Induced Neutropenia and Agranulocytosis
by: O. D. Ostroumova, et al.
Published: (2020-09-01)

Off-Label Drug Use in Pediatric Practice: Unsolved Problems
by: A. R. Titova, et al.
Published: (2015-10-01)

Postmarketing adverse events associated with onasemnogene abeparvovec: a real-world pharmacovigilance study
by: Tianyu Chen, et al.
Published: (2025-05-01)

Analysis of Errors Identified during Regulatory Review of Risk Management Plans Submitted as Part of Registration Dossiers
by: A. O. Lovkova, et al.
Published: (2023-12-01)

Methodology for Creating a Risk Management System for Drug-Drug Interactions
by: A. A. Taube, et al.
Published: (2024-03-01)

A Model for Predicting the Risk of Developing Drug-Induced Liver Injury During Therapy with Favipiravir
by: Yu. V. Shevchuk, et al.
Published: (2025-02-01)